OROX BioSciences, Inc. is an early stage biotechnology start-up based in San Diego, CA. Since 2018, the company has been dedicated to the efficient discovery and development of innovative small molecule drugs to address unmet medical needs in oncology and fibrosis. With a core technology focused on inhibiting soluble epoxide hydrolase (sEH) to ameliorate disease states, OROX BioSciences aims to harness the beneficial effects of modulating lipid metabolism in concert with secondary targets to improve therapeutic outcomes in cancer and fibrosis.
Specializing in understanding lipid metabolism and its interphase with disease states, OROX BioSciences boasts a team of experts from the academic, clinical, and biopharma settings. Their pipeline focuses on rapid and efficient progression, with therapeutic programs dedicated to discovering therapies for various forms of fibrosis, including idiopathic pulmonary fibrosis (IPF), as well as lung cancer. By addressing unmet medical needs in these areas, OROX BioSciences aims to make a significant impact on patient outcomes and quality of life.
Generated from the website